Contact Us
  • news-banner
  • NAD+ Market Game-Changer: EffePharm Leads “Clinical & Compliance” Charge at SupplySide Global 2025
    2025-11-05 NAD+ Market Game-Changer: EffePharm Leads “Clinical & Compliance” Charge at SupplySide Global 2025
    October 2025, Las Vegas – Top NAD+ Manufacturer Unveils UTHEVER® NMN, UthPeak® NMNH, & LipoAvail® Liposomal Tech to Capture NAD+ Supplement Boom
  • EffePharm to Lead Anti-Aging Innovation at SupplySide Global 2025: Unveiling NAD+ Breakthroughs & Liposomal Excellence
    2025-10-16 EffePharm to Lead Anti-Aging Innovation at SupplySide Global 2025: Unveiling NAD+ Breakthroughs & Liposomal Excellence
    EffePharm Takes Center Stage at SupplySide Global 2025 The global nutraceutical industry is abuzz as SupplySide Global 2025 prepares to kick off in Las Vegas this October 29-30, and EffePharm is set to steal the spotlight. As a trailblazer in NAD+ manufacturing, bulk NMN supply, and liposomal delivery technology, EffePharm is gearing up to showcase game-changing innovations that promise to redefine anti-aging and wellness at Booth #4555. For brands ready to capitalize on the $60 billion global anti-aging market, this is your opportunity to connect with a partner that combines clinical rigor, global regulatory expertise, and cutting-edge manufacturing capabilities. Let’s dive into what makes EffePharm the must-see exhibitor of the year. NAD+ Revolution: UTHEVER® NMN & UthPeak® NMNH, Science, Compliance, and Market Domination NAD+ (Nicotinamide Adenine Dinucleotide) isn’t just a buzzword; it’s the cellular “fuel” that powers energy production and DNA repair, and its decline with age is linked to everything from fatigue to age-related decline. EffePharm is doubling down on this critical pathway with two flagship innovations designed to meet post-FDA approval demand and set new standards for efficacy. UTHEVER® NMN: The Gold Standard in Bulk NMN, Now FDA-Approved The U.S. NAD+ market just got a seismic jolt: After…
+86(021)5770 9202
deal@effepharm.com
Contact Us
Need live support?
Chat with us now